Literature DB >> 27348438

Albumin-Oxanorbornadiene Conjugates Formed ex Vivo for the Extended Circulation of Hydrophilic Cargo.

Cody J Higginson1,2, Marsha R Eno3, Susan Khan3, Michael D Cameron3, M G Finn1,2.   

Abstract

Oxanorbornadiene dicarboxylate (OND) reagents were explored for the purpose of binding and releasing chemical cargos from endogenous circulating serum albumins. ONDs bearing gadolinium chelates as model cargos exhibited variable conjugation efficiencies with albumin in rat subjects that are consistent with the observed reactivity of each linker and their observed stability toward serum hydrolases in vitro. The terminal elimination rate from circulation was dependent on the identity of the OND used, and increased circulation time of gadolinium cargo was achieved for linkers bearing electrophilic fragments designed to react with cysteine-34 of circulating serum albumin. This binding of and release from endogenous albumin highlights the potential of OND linkers in the context of optimizing the pharmacokinetic parameters of drugs or diagnostic agents.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27348438      PMCID: PMC5523132          DOI: 10.1021/acschembio.6b00444

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  28 in total

1.  A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy.

Authors:  F Kratz; R Müller-Driver; I Hofmann; J Drevs; C Unger
Journal:  J Med Chem       Date:  2000-04-06       Impact factor: 7.446

Review 2.  Impact of albumin on drug delivery--new applications on the horizon.

Authors:  Bakheet Elsadek; Felix Kratz
Journal:  J Control Release       Date:  2011-09-16       Impact factor: 9.776

3.  A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy.

Authors:  A N Vis; A van der Gaast; B W G van Rhijn; T K Catsburg; C Schmidt; G H J Mickisch
Journal:  Cancer Chemother Pharmacol       Date:  2002-01-30       Impact factor: 3.333

4.  Gd-DOTA: characterization of a new paramagnetic complex.

Authors:  J C Bousquet; S Saini; D D Stark; P F Hahn; M Nigam; J Wittenberg; J T Ferrucci
Journal:  Radiology       Date:  1988-03       Impact factor: 11.105

5.  Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis.

Authors:  Andreas Wunder; Ulf Müller-Ladner; Ernst H K Stelzer; Jürgen Funk; Elena Neumann; Gerd Stehle; Thomas Pap; Hannsjörg Sinn; Steffen Gay; Christoph Fiehn
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

6.  Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.

Authors:  Felix Kratz; André Warnecke; Karin Scheuermann; Cornelia Stockmar; Jürgen Schwab; Peter Lazar; Peter Drückes; Norbert Esser; Joachim Drevs; Didier Rognan; Caterina Bissantz; Caterina Hinderling; Gerd Folkers; Iduna Fichtner; Clemens Unger
Journal:  J Med Chem       Date:  2002-12-05       Impact factor: 7.446

7.  The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage.

Authors:  Dirk Lebrecht; Andrea Geist; Uwe-Peter Ketelsen; Jörg Haberstroh; Bernhard Setzer; Felix Kratz; Ulrich A Walker
Journal:  Int J Cancer       Date:  2007-02-15       Impact factor: 7.396

8.  Acid pH in tumors and its potential for therapeutic exploitation.

Authors:  I F Tannock; D Rotin
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

9.  Macromolecular prodrug that provides the irinotecan (CPT-11) active-metabolite SN-38 with ultralong half-life, low C(max), and low glucuronide formation.

Authors:  Daniel V Santi; Eric L Schneider; Gary W Ashley
Journal:  J Med Chem       Date:  2014-03-06       Impact factor: 7.446

Review 10.  DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials.

Authors:  Felix Kratz
Journal:  Expert Opin Investig Drugs       Date:  2007-06       Impact factor: 6.206

View more
  7 in total

1.  Efficient Liver Targeting by Polyvalent Display of a Compact Ligand for the Asialoglycoprotein Receptor.

Authors:  Carlos A Sanhueza; Michael M Baksh; Benjamin Thuma; Marc D Roy; Sanjay Dutta; Cathy Préville; Boris A Chrunyk; Kevin Beaumont; Robert Dullea; Mark Ammirati; Shenping Liu; David Gebhard; James E Finley; Christopher T Salatto; Amanda King-Ahmad; Ingrid Stock; Karen Atkinson; Benjamin Reidich; Wen Lin; Rajesh Kumar; Meihua Tu; Elnaz Menhaji-Klotz; David A Price; Spiros Liras; M G Finn; Vincent Mascitti
Journal:  J Am Chem Soc       Date:  2017-02-23       Impact factor: 15.419

2.  Azabicyclic vinyl sulfones for residue-specific dual protein labelling.

Authors:  Enrique Gil de Montes; Ester Jiménez-Moreno; Bruno L Oliveira; Claudio D Navo; Pedro M S D Cal; Gonzalo Jiménez-Osés; Inmaculada Robina; Antonio J Moreno-Vargas; Gonçalo J L Bernardes
Journal:  Chem Sci       Date:  2019-03-18       Impact factor: 9.825

3.  Degradable Hydrogels for the Delivery of Immune-modulatory Proteins in the Wound Environment.

Authors:  Margarete Johnson; Jessica Lloyd; Srinivas Tekkam; Stephen N Crooke; Deborah A Witherden; Wendy L Havran; M G Finn
Journal:  ACS Appl Bio Mater       Date:  2020-07-18

4.  The Influence of Substitution on Thiol-Induced Oxanorbornadiene Fragmentation.

Authors:  Lucrezia De Pascalis; Mei-Kwan Yau; Dennis Svatunek; Zhuoting Tan; Srinivas Tekkam; K N Houk; M G Finn
Journal:  Org Lett       Date:  2021-04-14       Impact factor: 6.072

5.  Azanorbornadienes as Thiol-Reactive Cleavable Linkers.

Authors:  Lucrezia De Pascalis; Srinivas Tekkam; M G Finn
Journal:  Org Lett       Date:  2020-08-05       Impact factor: 6.072

Review 6.  Strategies for Preparing Albumin-based Nanoparticles for Multifunctional Bioimaging and Drug Delivery.

Authors:  Fei-Fei An; Xiao-Hong Zhang
Journal:  Theranostics       Date:  2017-08-23       Impact factor: 11.556

7.  Programmable multistage drug delivery to lymph nodes.

Authors:  Alex Schudel; Asheley Poole Chapman; Mei-Kwan Yau; Cody James Higginson; David Mark Francis; Margaret Patricia Manspeaker; Alexa Regina Chua Avecilla; Nathan Andrew Rohner; M G Finn; Susan Napier Thomas
Journal:  Nat Nanotechnol       Date:  2020-06-10       Impact factor: 40.523

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.